Cullinan Therapeutics, Inc. (CGEM)
收市後：
| 前收市價 | 23.81 |
| 開市 | 23.76 |
| 買盤 | 23.11 x 600 |
| 賣出價 | 23.18 x 100 |
| 今日波幅 | 22.75 - 24.26 |
| 52 週波幅 | 7.64 - 30.19 |
| 成交量 | |
| 平均成交量 | 745,382 |
| 市值 | 997.83M |
| Beta 值 (5 年，每月) | -0.00 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.69 |
| 業績公佈日 | 2024年8月08日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 33.00 |
BenzingaWhy Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in au
BenzingaCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
Cullinan Therapeutics Inc (NASDAQ:CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication. In SLE, the immune system of the body mistakenly attacks healthy tissue. The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated
Insider Monkey13 Best Booming Stocks to Buy Right Now
In this article, we will take a detailed look at the 13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now. Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market […]
